Agilent Technologies heads into its May 26 earnings report with options traders suddenly far more optimistic — a sharp reversal from months of defensive positioning that makes the setup worth examining closely.
The clearest signal this week is in the options market. The put/call ratio has collapsed to 0.52, its lowest level in at least a year, sitting almost two standard deviations below its 20-day average of 0.69. That marks a dramatic pivot from earlier in April, when the PCR was running above 0.75 and traders were stacking downside protection. The shift happened quickly — the ratio was above 0.73 as recently as April 17. Whatever drove that earlier caution appears to have faded fast, replaced by a notably call-heavy market that stands in contrast to the broader sector gloom.
Short interest adds nuance here. At just under 1.6% of the free float — with roughly 4.5 million shares estimated short — the bearish structural bet on Agilent is modest at best. It has drifted lower over the past month, down around 2% on the week and just under 1% over the month. Borrow conditions remain very easy: cost to borrow is a negligible 0.42% annualised, even after rising about 26% on the week in absolute terms. Availability in the lending pool is effectively unconstrained. There is no pressure here from short sellers, and no squeeze tension. The short score of 29.9 out of 100 reinforces that — this is a stock where the short community has little conviction.
The Street's posture is one of stubborn long-side optimism facing a bruising valuation reset. The consensus sits at hold, with four hold recommendations on record — but the recent changes from bellwether firms tell a more nuanced story. Barclays lowered its price target to $140 in mid-April while holding an Overweight rating. Evercore ISI cut its target earlier in April to the same $140 level. Both maintained positive ratings even as targets came down. Before that, Morgan Stanley trimmed its target to $160 in March, and a cluster of Buy-rated firms — UBS, TD Cowen, Wells Fargo — all ratcheted down targets in late February following what appears to have been a disappointing earnings print. The direction of travel on price targets has been consistently downward since February, with the stock now trading at $114.87, well below where most of these revised targets sit. The analyst return potential implied is nearly 40%, but that gap has been widening for months. On valuation, the EV/EBITDA multiple has been compressing — down about 0.24 turns over the past month to roughly 15.6x — while the PE has contracted about a turn on the week. The forward EPS growth score ranks in the 92nd percentile, a genuinely strong fundamental signal, though EPS surprise has been modest at only the 38th percentile.
Institutional ownership offers steady-state context rather than anything urgent. Vanguard holds 12.1% and added 1.6 million shares in Q1. MFS and T. Rowe Price were also incremental buyers over the quarter. These are quality-oriented, long-horizon holders — their continued presence reflects confidence in the business model even as sell-side targets decline. Insider activity has been low-conviction and entirely on the sell side: the CEO sold a small parcel in late February, and directors trimmed marginal positions in March. All trades were small and routine; there is nothing in the insider data that changes the picture.
The recent earnings history adds another layer. The last three prints produced negative one-day reactions averaging around 2% lower. The most recent print in late February saw the stock fall 2.8% on the day and extend losses to just over 3% over five sessions. Before that, a February 25 event produced a similar pattern. Agilent has not rewarded holders around earnings in recent quarters, even as the forward growth metrics look constructive. That pattern, combined with the month-ahead timing of the next results on May 26, is likely part of what drove the earlier put-heavy positioning — and the current call-heavy reading is a genuine reversal worth monitoring as the date approaches.
Close peers in the life sciences tools sector had a tough week. TMO, WAT, and RGEN all fell 10% or more over the week. BRKR dropped nearly 10%. A shed around 5.9% — a significant decline, but still the best relative performance among its most closely correlated peers. Whether that relative resilience reflects the options-driven call demand, or something more fundamental, is the question the May 26 print will answer.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
